Sellas Life Sciences Group Inc Galinpepimut-S Update Call Transcript
Hello, and thank you for standing by. Welcome to the SELLAS Life Science [REGAL] Conference Call and Webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to introduce your host, Allison Soss, Investor Relations. Please go ahead.
Good morning, everyone. The focus of today's call is SELLAS's Phase III clinical trial of GPS in patients with acute myeloid leukemia and second remission, the REGAL study.
Dr. Angelos Stergiou, the company's President and Chief Executive Officer, will begin today's call with some important updates regarding the REGAL, [according] REGAL; and then introduce our additional speaker, Dr. Yair Levy of Baylor University Medical Center; as well as Dr. Dragan Cicic, SELLASâs SVP of Clinical Development, who will participate in the Q&A.
Following the presentations, we will hold a Q&A session as we will likely not have time to answer every question, we will give priority to questions from the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |